Randi Altschul, CEO is an entrepreneur/inventor of new products and an Editorial Advisor/Columnist for the Pharmaceutical Manufacturing and Packing Sourcer International magazine. She is the creator of the world’s first disposable cell phone (General Electric), the credit card phone, the programmable debit card, the paper laptop and she is the only woman to be named a “World’s Notable Inventor” by the World Intellectual Property Organization (WIPO). Her drug development company in collaboration with NIH/NIAID have demonstrated success in the development of novel small molecule anti-viral and antibiotic therapeutics. Her chemo-sensitizer for breast cancer and ovarian cancer is planned for human trials. Her Smart Pills are considered a game changer in abuse deterrent technologies. Her anti-addiction drug is being funded for clinical trials by the Department of Defense for the Veterans Administration on PTSD/alcoholism and CDMRP is funding her PTSD/opioid drug trials.
John Gregg, MBA, COO is a more than 25 year veteran of the pharmaceutical industry. His experience and expertise range from Director of the Product Evaluation Group for Global Analytics at Pfizer Global Pharmaceuticals to the Specialty Market Research Team at Novartis and the Marketing services of Johnson & Johnson and Bristol-Myers Squibb. John’s ability in targeting and commercialization of unique and novel products brings a wealth of opportunity to the Pop Test & Palisades Therapeutics companies
Robert Foerster, MBA, CFO, Business Development. He is a 28 year Pfizer veteran. He started in the Controllers Division as a Pharmaceutical and R&D Business Analyst, and from there became a Project Manager for operations in Europe, Asia and Africa. His next assignment was as Business Development Director, based in Brussels, for Asia, Africa and Middle East. He then worked as Director Financial Operations Africa and Middle East. Following that, he was promoted to Director/Team Leader New Product Development, responsible for the Neuroscience, Oncology and Metabolic Disease portfolios. He then moved to Tokyo, where he was Sr. Director Business Development Japan, responsible for all development pipeline programs, licensing / partner operations, and strategic planning. Upon returning to New York, he was Sr. Director Commercial Development Emerging Markets. Bob joined the Pop Test & Palisades Therapeutics family of companies in 2015.
Neil Theise, MD, Lead Scientist. He is a physician/scientist and an international thought leader in clinical medicine (liver disease) and basic science (adult stem cells, human anatomy), publishing in top journals including Cell, Science, Nature, The Lancet. He is a Professor of Pathology at a major New York City medical school. His recent elucidation of a completely novel anatomy of the human interstitium garnered global attention and may constitute a previously unappreciated organ constituting 20% of the fluid volume of the human body. He has been a member of the Pop Test & Palisades Therapeutics family of companies from its inception and has been directly involved with development of all its inventions, devices, and pharmacological agents.
Razvan Ene, PhD, Director , World Wide Operations. He completed management studies at Motorola University where he also lectured on Risk Management. He holds an Applied Physics MSc and a PhD in Electronics and Telecommunications from Turin Polytechnic, Italy. After Motorola he was R&D Director of DDi’s Engineering Services Division in the United States. He went on to co-found and be CEO of the innovative Synapto company, dedicated to the development of Smart magnetic sensors. In this last decade, he has been at Elco Group, first as Managing Director of the Engineering Service division and now overseeing all manufacturing operations and research and development on a global level. He is also CEO of Elco China and Cadlog China.
Ernest R. Nuzzo, Esq., General Counsel. He has been practicing law for more than 50 years and has been the General Counsel for the Pop Test & Palisades Therapeutics Companies since their inception. He was previously a General Counsel for a Fortune 500 company.